Latest news with #HLSTherapeuticsInc
Cision Canada
28-04-2025
- Business
- Cision Canada
HLS Therapeutics to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
TORONTO, April 28, 2025 /CNW/ - HLS Therapeutics Inc. (HLS or the Company) (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that Brian Walsh, Chief Commercial Officer, will present at the 2025 Bloom Burton & Co. Healthcare Investor Conference, which takes place May 5-6, 2025 at the Metro Toronto Convention Centre, in downtown Toronto. Details on the Company's presentation are as follows: Webcast and replay information for this event will also be available on the Event Page in the Investor Relations section of HLS's website. The replay will be available for 90 days. ABOUT HLS THERAPEUTICS INC. Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting unmet needs in the treatment of psychiatric disorders and cardiovascular disease. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: FORWARD LOOKING INFORMATION This release includes forward-looking statements regarding HLS and its business. Such statements are based on the current expectations and views of future events of HLS's management. In some cases the forward-looking statements can be identified by words or phrases such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify forward-looking statements, including, among others, statements with respect to HLS's pursuit of additional product and pipeline opportunities in certain therapeutic markets, statements regarding growth opportunities, expectations regarding financial performance, and the NCIB and ASPP. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting HLS, including risks relating to the specialty pharmaceutical industry, risks related to the regulatory approval process, economic factors and many other factors beyond the control of HLS. Forward-looking statements and information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause HLS's actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statement or information. Accordingly, readers should not place undue reliance on any forward-looking statements or information. A discussion of the material risks and assumptions associated with this release can be found in the Company's Annual Information Form dated March 12, 2025, and Management's Discussion and Analysis dated March 12, 2025, both of which have been filed on SEDAR+ and can be accessed at Accordingly, readers should not place undue reliance on any forward-looking statements or information. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and HLS undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. SOURCE HLS Therapeutics Inc.
Cision Canada
24-04-2025
- Business
- Cision Canada
HLS Therapeutics to Host Q1 2025 Financial Results Conference Call
TORONTO, April 24, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 2025 financial results on Thursday, May 8, 2025. The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Craig Millian, Chief Executive Officer; John Hanna, Chief Financial Officer; and Brian Walsh, Chief Commercial Officer. Slides to accompany management's prepared remarks will be available to view via the webcast. CONFERENCE ID: 41562 DATE: Thursday, May 8, 2025 TIME: 8:30 a.m. ET WEBCAST LINK: TRADITIONAL DIAL-IN NUMBER: 1-888-699-1199 or 1-416-945-7677 RAPIDCONNECT: To instantly join the conference call by phone, please use the following URL to easily register and be connected into the conference call automatically: TAPED REPLAY: 1-888-660-6345 or 1-646-517-4150 REPLAY CODE: 41562# The taped replay will be available for 14 days and the archived webcast will be available for 365 days. A link to the live audio webcast of the conference call will also be available on the events page of the investors section of HLS Therapeutics' website at Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to hear the webcast. ABOUT HLS THERAPEUTICS INC. Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products that address unmet needs in the treatment of psychiatric disorders and cardiovascular disease. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit:
Yahoo
22-03-2025
- Business
- Yahoo
HLS Therapeutics Inc.'s (TSE:HLS) biggest owners are individual investors who got richer after stock soared 18% last week
Significant control over HLS Therapeutics by individual investors implies that the general public has more power to influence management and governance-related decisions A total of 4 investors have a majority stake in the company with 59% ownership Recent purchases by insiders Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Every investor in HLS Therapeutics Inc. (TSE:HLS) should be aware of the most powerful shareholder groups. We can see that individual investors own the lion's share in the company with 39% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company. Clearly, individual investors benefitted the most after the company's market cap rose by CA$22m last week. Let's take a closer look to see what the different types of shareholders can tell us about HLS Therapeutics. Check out our latest analysis for HLS Therapeutics Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing. As you can see, institutional investors have a fair amount of stake in HLS Therapeutics. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of HLS Therapeutics, (below). Of course, keep in mind that there are other factors to consider, too. Our data indicates that hedge funds own 39% of HLS Therapeutics. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Our data shows that Polar Asset Management Partners Inc. is the largest shareholder with 20% of shares outstanding. With 19% and 10% of the shares outstanding respectively, Stadium Capital Management, LLC and Mawer Investment Management Ltd. are the second and third largest shareholders. To make our study more interesting, we found that the top 4 shareholders control more than half of the company which implies that this group has considerable sway over the company's decision-making. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future. While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. Our most recent data indicates that insiders own less than 1% of HLS Therapeutics Inc.. It appears that the board holds about CA$1.0m worth of stock. This compares to a market capitalization of CA$149m. Many investors in smaller companies prefer to see the board more heavily invested. You can click here to see if those insiders have been buying or selling. With a 39% ownership, the general public, mostly comprising of individual investors, have some degree of sway over HLS Therapeutics. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. It's always worth thinking about the different groups who own shares in a company. But to understand HLS Therapeutics better, we need to consider many other factors. For instance, we've identified 1 warning sign for HLS Therapeutics that you should be aware of. Ultimately the future is most important. You can access this free report on analyst forecasts for the company. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
